We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+14.17%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$883M
AUM Growth
+$301M
Cap. Flow
+$204M
Cap. Flow %
23.13%
Top 10 Hldgs %
65.86%
Holding
75
New
21
Increased
22
Reduced
4
Closed
17

Top Buys

Rank Stock Value
1
ITRM
Iterum Therapeutics
ITRM
+$20.8M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$16.7M
3
AGN
Allergan plc
AGN
+$16.4M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$15.4M
5
CELG
Celgene Corp
CELG
+$15.3M

Top Sells

Rank Stock Value
1
NCNA
NuCana
NCNA
+$98.5M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$16.5M
3
APLS
Apellis Pharmaceuticals
APLS
+$6.8M
4
ATYR
aTyr Pharma
ATYR
+$4.95M
5
BMY icon
Bristol-Myers Squibb
BMY
+$951K

Sector Composition

Rank Sector Weight
1 Healthcare 81.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMED
51
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$915K 0.1%
396,244
+329,211
+491% +$959K
CCXI
52
DELISTED
ChemoCentryx, Inc.
CCXI
$899K 0.1%
+68,258
New +$816K
SNDX icon
53
Syndax Pharmaceuticals
SNDX
$1.84B
$693K 0.08%
98,613
+86,489
+713% +$849K
FTSV
54
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$379K 0.04%
+23,700
New +$368K
AFMD
55
DELISTED
Affimed
AFMD
– –
-11,083
Closed -$205K
ARDX icon
56
Ardelyx
ARDX
$1.24B
– –
-99,166
Closed -$501K
BMY icon
57
Bristol-Myers Squibb
BMY
$127B
– –
-15,033
Closed -$951K
CDTX
58
DELISTED
Cidara Therapeutics
CDTX
– –
-648
Closed -$52K
EXEL icon
59
CALL
Exelixis
EXEL
$13.9B
– –
-9,300
Closed -$206K
IONS icon
60
Ionis Pharmaceuticals
IONS
$9.35B
– –
-8,476
Closed -$374K
IOVA icon
61
Iovance Biotherapeutics
IOVA
$2.23B
– –
-30,958
Closed -$523K
MNOV icon
62
MediciNova
MNOV
$65M
– –
-32,875
Closed -$336K
REGN icon
63
Regeneron Pharmaceuticals
REGN
$68.8B
– –
-1,304
Closed -$449K
RIGL icon
64
PUT
Rigel Pharmaceuticals
RIGL
$680M
– –
-7,130
Closed -$252K
ATYR
65
aTyr Pharma
ATYR
$46.4M
– –
-133,295
Closed -$4.95M
MRTX
66
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-8,688
Closed -$267K
CYTO
67
DELISTED
Altamira Therapeutics Ltd
CYTO
$0 ﹤0.01%
18
-80
-82% -$844K
SPPI
68
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-15,000
Closed -$241K
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
– –
-16,847
Closed -$605K
SRRA
70
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-2,453
Closed -$203K
STML
71
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-12,640
Closed -$193K
ONCS
72
DELISTED
OncoSec Medical Incorporated
ONCS
– –
-304
Closed -$126K
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2018 Portfolio in Review

As of Q2 2018, Sofinnova Investments held 75 positions worth $883M, up 52% from $582M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments deployed $204M of net new capital in Q2 2018, opening 21 new positions and adding to 22 existing holdings. Its largest new stake was Iterum Therapeutics: 115,101 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was NuCana, an estimated $98.5M trimmed.

  • Sofinnova Investments's largest Q2 2018 buy was Iterum Therapeutics: 115,101 shares worth $18.8M.
  • Sofinnova Investments added most to Allergan plc in Q2 2018, an estimated $16.4M increase.
  • Sofinnova Investments's biggest Q2 2018 reduction was NuCana, cutting an estimated $98.5M.
  • Sofinnova Investments fully exited aTyr Pharma in Q2 2018, selling an estimated $4.95M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $883M portfolio in Q2 2018.
  • Sofinnova Investments opened 21 new positions and closed 17 in Q2 2018.
  • Sofinnova Investments's portfolio value rose 52% quarter-over-quarter to $883M.

Based on Sofinnova Investments's 13F filing for Q2 2018, filed 14 Aug 2018.